Ramm Pharma (RAMM) AI Stock Analysis

Top Page

Ramm Pharma

(CNQX:RAMM)

Select Model

Rating:38Underperform

Price Target:CAD 0.01▼(-10.00% Downside)

Action:reiterated

Date:10/03/26

The overall stock score is driven primarily by extremely weak financial performance and persistent cash burn, which point to high ongoing funding risk and limited visibility on a path to sustainable profitability. This is reinforced by a long-running downtrend in the share price, extreme bearish technical signals such as very low RSI and negative MACD, and an unattractive valuation profile in which a slightly negative P/E, lack of dividend income, and indications of overvaluation outweigh any appeal of the very low nominal share price[1][3][5][6][8][10][11][12][13].

Positive Factors

Low leverageVery low debt relative to equity limits refinancing and balance-sheet stress, preserving flexibility while the company works through losses. This is a meaningful stabilizer over the next several quarters, even though it does not offset weak operating performance.

Negative Factors

Sharp revenue declineTTM revenue declined 32.9%, showing weakening demand or traction relative to prior periods. A shrinking sales base makes it harder to absorb operating costs, reach break-even, and finance growth internally, leaving recovery dependent on restoring revenue momentum.

Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 1.19M
Dividend Yield: ―
Average Volume (3M): 66.38K
Price to Earnings (P/E): -0.1
Beta (1Y): -3.69
Revenue Growth: -66.40%
EPS Growth: 31.38%
Country: Canada
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Ramm Pharma Business Overview & Revenue Model

Company Description

RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other can...

Ramm Pharma Financial Statement Overview

Summary

Financial results show sharply lower revenue versus prior years, recurring large operating and net losses, deeply negative profit margins, shrinking assets and equity, and persistently negative operating and free cash flow, indicating very high financial risk and a weak, deteriorating earnings profile.

Income Statement

12Very Negative

Balance Sheet

30Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Jan 2026	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	1.27M	3.36M	4.34M	5.07M	3.90M	4.12M
Gross Profit	-59.57K	373.93K	1.76M	381.82K	530.50K	-7,641
EBITDA	-3.67M	-3.78M	-15.23M	-6.30M	-19.91M	-6.36M
Net Income	-9.08M	-8.91M	-16.50M	-7.72M	-20.96M	-7.11M
Balance Sheet
Total Assets	6.72M	9.27M	16.75M	32.30M	39.31M	59.71M
Cash, Cash Equivalents and Short-Term Investments	147.13K	803.88K	814.04K	5.12M	9.77M	17.16M
Total Debt	169.55K	80.39K	188.31K	405.14K	683.70K	32.16K
Total Liabilities	2.97M	3.57M	3.11M	2.84M	3.72M	3.32M
Stockholders Equity	3.75M	5.70M	13.63M	29.46M	35.59M	56.39M
Cash Flow
Free Cash Flow	-1.26M	-1.06M	-4.05M	-4.45M	-6.08M	-4.25M
Operating Cash Flow	-1.26M	-1.06M	-4.00M	-4.34M	-5.91M	-3.82M
Investing Cash Flow	957.55K	1.22M	-47.43K	126.58K	-1.15M	-6.83M
Financing Cash Flow	-72.53K	-154.07K	-258.23K	-409.97K	-353.77K	-190.33K

Ramm Pharma Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.01Positive

100DMA0.01Negative

200DMA0.02Negative

Market Momentum

MACD-0.00Negative

RSI8.17Positive

STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 8.17 is Positive, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:RAMM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:INNO	56Neutral	CAD 8.55M	-6.55	-19.37%	―	-19.20%	42.54%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:LABS	49Neutral	CAD 27.77M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:ATLE	42Neutral	CAD 41.96M	-0.76	-2099.75%	―	-100.00%	94.43%
TSE:PCLO	42Neutral	CAD 9.34M	-2.67	28.59%	―	0.90%	57.73%
TSE:AVCN	41Neutral	CAD 14.11M	-3.24	-108.44%	―	-0.23%	-142.54%
TSE:RAMM	38Underperform	CAD 1.19M	-0.13	-194.41%	―	-66.40%	31.38%

* Healthcare Sector Average

Performance Comparison

TSE:RAMM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:RAMM	Ramm Pharma Corp	0.01	-0.01	-50.00%
TSE:ATLE	Willow Biosciences	0.09	-0.07	-43.75%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-13.33%
TSE:PCLO	Pharmacielo	0.05	0.01	11.11%
TSE:AVCN	Avicanna Inc	0.10	-0.16	-60.38%
TSE:INNO	Innocan Pharma Corporation	1.90	-16.10	-89.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 03, 2026

Ramm Pharma AI Stock Analysis